RxDoctor Payments Data

David Schuchman, MD

Cardiovascular Disease · Littleton, CONPI 1336231273

Payments from drug & device makers

$1,933in general payments, 2019–2025

Across 110 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$361
  • Amgen$361
  • Pfizer$354
  • E.r. Squibb & Sons, L.L.C.$316
  • Johnson & Johnson$126
  • Boehringer Ingelheim$86
  • plus $331 from 13 others

What the payments were for

  • Food & beverage$1,933100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,933 in reported general payments places this provider in the 45th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$306,191
Medicare patients
1,323
Services billed
3,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban527$733,225
Repatha SureclickEvolocumab365$346,718
Praluent PenAlirocumab111$98,138
JardianceEmpagliflozin73$90,572
XareltoRivaroxaban53$87,475
Repatha SyringeEvolocumab30$37,453
EntrestoSacubitril/Valsartan16$28,540
Repatha PushtronexEvolocumab23$24,385
Rosuvastatin Calcium824$9,773
Metoprolol Succinate451$5,824
Nebivolol Hcl97$5,734
Atorvastatin Calcium541$4,676
Losartan Potassium468$4,354
Ezetimibe146$3,317
Eplerenone27$3,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$354$733,225527 claims
Boehringer IngelheimJardiance$86$90,57273 claims
Johnson & JohnsonXarelto$126$87,47553 claims
NovartisEntresto$361$28,54016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →